VTRS Stock Analysis
NMS · Healthcare · Drug Manufacturers - Specialty & Generic
$17.75
-0.08 (-0.45%)
VTRS Interactive Price Chart & Trading Signals
VTRS Stock Snapshot — Valuation, Risk & Technical Signals
VTRS Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$20.39B
P/E Ratio
—
Forward P/E
6.64
PEG Ratio
3.24
P/B Ratio
1.41
EPS
$-0.37
Dividend Yield
2.69%
52W Range
$9.47 – $18.39
Beta
0.88
Volume
0.6M
ROE
-2.8%
Profit Margin
-2.8%
Revenue Growth
4.9%
Gross Margin
40.3%
EV/EBITDA
7.59
Analyst Target
$19.40
Forward P/E of 6.6x suggests earnings compression ahead. Price-to-book is 1.41x. EV/EBITDA sits at 7.59x. Market capitalization is $20.39B. Revenue is growing at 4.9% on a trailing basis. Beta of 0.88 indicates market-average volatility.
Analyst Consensus
Recommendation
Buy
Low Target
$13.00
Mean Target
$19.40
High Target
$25.00
Based on 10 analysts
About VTRS
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
VTRS Deep Dive Analysis
Bottom Line
Verdict
UndervaluedBest for
Value-oriented investorsWatch out for
None flaggedNon-zero inputs
3/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Viatris Inc. (VTRS) trades below our multi-model fair value estimate of $39.93 by approximately 125.0%. Recent growth metrics show revenue growth of 4.9%. Risk profile: beta of 0.88. Consensus: buy.
Valuation, Growth & Risk
Valuation
Undervalued
Price sits below our estimate of fair value.
Growth
Stable
Rev 4.9%
Revenue is moving sideways.
Valuation Snapshot
Viatris Inc. (VTRS) trades below our multi-model fair value estimate of $39.93 by approximately 125.0%. Forward P/E of 6.6x indicates stable forward expectations. Price-to-sales is 1.4x. Price-to-book is 1.4x. EV/EBITDA sits at 7.6x. Market capitalization is $20.39B.
Why it matters: Buying below fair value can create a margin of safety, but always check earnings quality.
Growth & Profitability
Revenue is growing at 4.9% on a trailing basis. Return on assets is 2.7%.
Why it matters: Stable revenue is fine, but watch for margin pressure that could limit profit growth.
Risk Profile
Beta of 0.88 indicates market-average volatility. Net debt position is $12.11B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $19.40 implies 9.3% upside. Target range spans $13.00 to $25.00. 10 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Investor Fit
The combination of undervaluation and moderate risk may suit value-oriented investors. Free cash flow yield of 9.1% is attractive for cash-flow-focused investors.
Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
VTRS Undervalued
Viatris Inc. (VTRS) trades below our multi-model fair value estimate of $39.93 by approximately 125.0%.
Frequently Asked Questions
ValuationIs VTRS stock overvalued right now?
ValuationWhat is VTRS fair value based on current fundamentals?
RiskHow risky is VTRS compared with other stocks?
GrowthIs VTRS still growing?
AnalystWhat do analysts think about VTRS?
DividendDoes VTRS pay a dividend?
CatalystWhat could change the investment case for VTRS?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.